Results 91 to 100 of about 19,649 (222)

Characterization of a novel variant BCR–ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring [PDF]

, 2016
Molecular monitoring of BCR–ABL1 transcript levels using quantitative polymerase chain reaction is an essential part of the modern management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Cross, van Dongen, Burmeister, Chiarella, Pane, Langabeer, Baccarani, O’Brien, Gabert, Rubinstein, Dessars, Matsushita, Jurcek, McCarron, Huet, Frederick, Sonu, Branford, Cross, Marin, Mahon, Langabeer   +21 more
core   +2 more sources

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem, Abdul Qayyum, Abid Jamil, Abid Taj, Ahmad Khalid, Ammara Tahir, Ijaz Shah, Mahwish Khan, Mubashar Naqvi, Mudassar Iqbal, Muhammad Abbad, Muhammad Ferhan, Muhammad Khalid, Najeeb ur-Rehman, Riaz ul-Haq, Shahid Baig, Tanveer Akhtar, Tariq Gill, Weng Qin, Zafar Iqbal   +19 more
core   +1 more source

Drug target optimization in chronic myeloid leukemia using innovative computational platform. [PDF]

, 2015
Chronic Myeloid Leukemia (CML) represents a paradigm for the wider cancer field. Despite the fact that tyrosine kinase inhibitors have established targeted molecular therapy in CML, patients often face the risk of developing drug resistance, caused by ...
Benque, David, Chuang, Ryan, Cook, Byron, Fisher, Jasmin, Gottgens, Berthold, Hall, Benjamin A, Ishtiaq, Samin, Koschmieder, Steffen, Piterman, Nir, Taylor, Alex, Vardi, Moshe   +10 more
core   +2 more sources

Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang, Yujie Shan, Shihong Xu, Jing Wang, Meng Luo, Jiaojiao Zhou, Qishan Chen   +6 more
wiley   +1 more source

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms [PDF]

, 2016
Background Acquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM binding and kinase inhibition in patients with chronic myelogenous leukemia (CML).
Bing Z. Carter, Chong Zhao, Dan Zang, Hongbiao Huang, Huidan Long, Jinbao Liu, Jinghong Chen, Jinjie Wu, Li Yang, Peiquan Zhang, Xianping Shi, Xiaoying Lan, Xin Chen, Xuejun Wang   +13 more
core   +2 more sources

The Anti‐Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies

Food Science &Nutrition, Volume 13, Issue 9, September 2025.
Curcumin suppresses chronic myeloid leukemia progression through multiple molecular pathways. It inhibits BCR‐ABL1, modulates miR‐21, PKCα, and PTEN, activates DR4/DR5, blocks G2/M cell cycle progression, and inhibits HDAC. These actions collectively promote apoptosis, enhance tumor suppressor expression, and reduce leukemic cell proliferation ...
Hossein Bahari, Zeinab Salim, Leila Kardanpour, Hosein Kouchaki, Fatemeh Shoja, Iman Rahnama, Arezoo Faridzadeh, Maryam Ranjbar Zahedani   +7 more
wiley   +1 more source

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib [PDF]

, 2009
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such
David Masiello, Gerry Gorospe, Allen S Yang, CL Sawyers, CR Bartram, J Groffen, TG Lugo, RH Alvarez, HM Kantarjian, BJ Druker, T Hughes, JL Steegman, LJ Lombardo, T O'Hare, T O'Hare, J Cortes, F Guilhot, A Hochhaus, MJ Mauro, NP Shah, HJ Khoury, H de Lavallade, A Quintas-Cardama, A Bergeron, S Blake, U Rix, A Hochhaus, HM Kantarjian, P Le Coutre, O Ottmann   +29 more
core   +1 more source

Successful Allogeneic Stem Cell Transplant for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia After Pneumonectomy for Pulmonary Mucormycosis: A Case Report and Review of the Literature

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT The incidence of relapsed Philadelphia chromosome‐negative acute lymphoblastic leukemia in adults is estimated to be 40%–50%. Allogeneic stem cell transplantation can improve survival in relapsed acute lymphoblastic leukemia; however, impaired pulmonary function is detrimental for surviving the transplantation process.
Alexander O'Hara, Sanja Zepcan, Stephanie Tsai, Imran Puthawala, Jorgena Kosti‐Schwartz   +4 more
wiley   +1 more source

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy [PDF]

, 2017
At diagnosis, about 5% of Chronic Myeloid Leukemia (CML) patients lacks Philadelphia chromosome (Ph), despite the presence of the BCR/ABL rearrangement.
Ameli, Gaia, Baccarani, Michele, Baldazzi, Carmen, Bochicchio, Maria Teresa, Castagnetti, Fausto, Cavo, Michele, Gugliotta, Gabriele, Luatti, Simona, Martinelli, Giovanni, Marzocchi, Giulia, Rosti, Gianantonio, Soverini, Simona, Testoni, Nicoletta, Tiribelli, Mario   +13 more
core   +1 more source

Unveiling the Burden of Leukemia in Eritrea (2010–2020): Chronic Leukemia Stability, Rising ALL Incidence, and the Enigma of CML in a Low‐Resource Setting

Cancer Reports, Volume 8, Issue 6, June 2025.
ABSTRACT Background and Aims Little research has been conducted on the epidemiology of leukemia in Eritrea. In this retrospective study, we evaluated the burden and trends of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and overall leukemia in Eritrea ...
Daniel Mebrahtu Abraha, Samuel Tekle Mengistu, Efriem Ghirmay, Eden Gebresilassie, Ghirmay Embaye Zerat, Rahwa Kokob, Asmeret Tesfazghi, Solomon Negash, Tsega Daniel, Salih Mohammed, Oliver Okoth Achila   +10 more
wiley   +1 more source